Mesoblast (MSB.AX) Stock Price

Mesoblast Price

🇦🇺ASX·CLOSED
1.47USD
Market closed
Today +/-
-0.07 USD
Today %
-4.43 %

Mesoblast (MSB.AX) Stock | ISIN AU000000MSB8 | WKN A0DNPW. The current Mesoblast stock price is 1.47 USD (2026). Revenue is 128.05 M USD. Net income is -171.81 M USD. The P/E ratio is -10.32. Market capitalization is 1.77 B USD. Mesoblast operates in the Health sector.

Mesoblast stock price

Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Mesoblast over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Mesoblast stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Mesoblast's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Mesoblast Stock Price History
DateMesoblast Price
3/27/20261.47 USD
3/26/20261.54 USD
3/25/20261.54 USD
3/24/20261.45 USD
3/23/20261.43 USD
3/20/20261.45 USD
3/19/20261.47 USD
3/18/20261.5 USD
3/17/20261.44 USD
3/16/20261.45 USD
3/13/20261.5 USD
3/12/20261.51 USD
3/11/20261.56 USD
3/10/20261.54 USD
3/9/20261.49 USD
3/6/20261.65 USD
3/5/20261.56 USD
3/4/20261.45 USD
3/3/20261.42 USD
3/2/20261.45 USD
2/27/20261.59 USD
2/26/20261.72 USD
2/25/20261.67 USD
2/24/20261.63 USD
2/23/20261.66 USD
2/20/20261.7 USD
2/19/20261.72 USD
2/18/20261.74 USD
2/17/20261.71 USD
2/16/20261.72 USD
2/13/20261.68 USD
2/12/20261.74 USD
2/11/20261.82 USD
2/10/20261.78 USD
2/9/20261.7 USD
2/6/20261.59 USD
2/5/20261.69 USD
2/4/20261.76 USD
2/3/20261.76 USD
2/2/20261.75 USD
1/30/20261.79 USD
1/29/20261.83 USD
1/28/20261.9 USD
1/27/20261.91 USD
1/23/20261.91 USD
1/22/20261.89 USD
1/21/20261.78 USD
1/20/20261.8 USD
1/19/20261.81 USD
1/16/20261.88 USD
1/15/20261.93 USD
1/14/20261.91 USD
1/13/20261.94 USD
1/12/20262.02 USD
1/9/20262.17 USD
1/8/20262.1 USD
1/7/20261.93 USD
1/6/20261.93 USD
1/5/20261.96 USD
1/2/20261.96 USD
12/31/20251.93 USD
12/30/20251.99 USD
12/29/20252 USD
12/24/20252.07 USD
12/23/20252.05 USD
12/22/20252.07 USD
12/19/20252.05 USD
12/18/20251.98 USD
12/17/20251.99 USD
12/16/20251.96 USD
12/15/20251.93 USD
12/12/20251.96 USD
12/11/20251.94 USD
12/10/20252.04 USD
12/9/20251.99 USD
12/8/20251.94 USD
12/5/20251.88 USD
12/4/20251.81 USD
12/3/20251.79 USD
12/2/20251.83 USD
12/1/20251.9 USD
11/28/20251.92 USD
11/27/20251.91 USD
11/26/20251.93 USD
11/25/20251.7 USD
11/24/20251.64 USD
11/21/20251.64 USD
11/20/20251.64 USD
11/19/20251.62 USD
11/18/20251.61 USD
11/17/20251.64 USD
11/14/20251.58 USD
11/13/20251.64 USD
11/12/20251.66 USD
11/11/20251.64 USD
11/10/20251.62 USD
11/7/20251.57 USD
11/6/20251.62 USD
11/5/20251.71 USD
11/4/20251.71 USD
11/3/20251.75 USD
10/31/20251.79 USD
10/30/20251.78 USD
10/29/20251.79 USD
10/28/20251.81 USD
10/27/20251.81 USD
10/24/20251.81 USD
10/23/20251.84 USD
10/22/20251.93 USD
10/21/20252.05 USD
10/20/20251.88 USD
10/17/20251.87 USD
10/16/20251.99 USD
10/15/20251.93 USD
10/14/20251.96 USD
10/13/20252 USD
10/10/20252.04 USD
10/9/20252.1 USD
10/8/20252.06 USD
10/7/20251.89 USD
10/6/20251.83 USD
10/3/20251.95 USD
10/2/20251.79 USD
10/1/20251.7 USD
9/30/20251.69 USD
9/29/20251.72 USD
9/26/20251.7 USD
9/25/20251.78 USD
9/24/20251.74 USD
9/23/20251.75 USD
9/22/20251.79 USD
9/19/20251.73 USD
9/18/20251.69 USD
9/17/20251.64 USD
9/16/20251.65 USD
9/15/20251.64 USD
9/12/20251.57 USD
9/11/20251.64 USD
9/10/20251.65 USD
9/9/20251.59 USD
9/8/20251.57 USD
9/5/20251.5 USD
9/4/20251.41 USD
9/3/20251.38 USD
9/2/20251.42 USD
9/1/20251.43 USD
8/29/20251.54 USD
8/28/20251.71 USD
8/27/20251.76 USD
8/26/20251.74 USD
8/25/20251.72 USD
8/22/20251.68 USD
8/21/20251.67 USD
8/20/20251.64 USD
8/19/20251.69 USD
8/18/20251.74 USD
8/15/20251.78 USD
8/14/20251.72 USD
8/13/20251.63 USD
8/12/20251.62 USD
8/11/20251.61 USD
8/8/20251.64 USD
8/7/20251.67 USD
8/6/20251.71 USD
8/5/20251.7 USD
8/4/20251.68 USD
8/1/20251.67 USD
7/31/20251.68 USD
7/30/20251.73 USD
7/29/20251.76 USD
7/28/20251.76 USD
7/25/20251.79 USD
7/24/20251.83 USD
7/23/20251.69 USD
7/22/20251.62 USD
7/21/20251.64 USD
7/18/20251.69 USD
7/17/20251.28 USD
7/16/20251.22 USD
7/15/20251.2 USD
7/14/20251.18 USD
7/11/20251.17 USD
7/10/20251.17 USD
7/9/20251.11 USD
7/8/20251.12 USD
7/7/20251.14 USD
7/4/20251.15 USD
7/3/20251.15 USD
7/2/20251.18 USD
7/1/20251.3 USD
6/30/20251.18 USD
6/27/20251.17 USD
6/26/20251.15 USD
6/25/20251.14 USD
6/24/20251.12 USD
6/23/20251.11 USD
6/20/20251.15 USD
6/19/20251.2 USD
6/18/20251.27 USD
6/17/20251.3 USD
6/16/20251.32 USD
6/13/20251.28 USD
6/12/20251.31 USD
6/11/20251.28 USD
6/10/20251.32 USD
6/6/20251.24 USD
6/5/20251.25 USD
6/4/20251.23 USD
6/3/20251.14 USD
6/2/20251.13 USD
5/30/20251.19 USD
5/29/20251.18 USD
5/28/20251.19 USD
5/27/20251.16 USD
5/26/20251.15 USD
5/23/20251.21 USD
5/22/20251.2 USD
5/21/20251.2 USD
5/20/20251.24 USD
5/19/20251.23 USD
5/16/20251.23 USD
5/15/20251.28 USD
5/14/20251.26 USD
5/13/20251.29 USD
5/12/20251.23 USD
5/9/20251.21 USD
5/8/20251.23 USD
5/7/20251.22 USD
5/6/20251.23 USD
5/5/20251.27 USD
5/2/20251.31 USD
5/1/20251.34 USD
4/30/20251.27 USD
4/29/20251.3 USD
4/28/20251.26 USD
4/24/20251.27 USD
4/23/20251.2 USD
4/22/20251.14 USD
4/17/20251.17 USD
4/16/20251.15 USD
4/15/20251.21 USD
4/14/20251.17 USD
4/11/20251.11 USD
4/10/20251.23 USD
4/9/20251.14 USD
4/8/20251.25 USD
4/7/20251.14 USD
4/4/20251.25 USD
4/3/20251.31 USD
4/2/20251.33 USD
4/1/20251.37 USD
Access this data via the Eulerpool API
Get Free API Key

Mesoblast Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
2.11 M USD
-4.7 M USD
-6.2 M USD
Jan 1, 2007
1.32 M USD
-5.5 M USD
-6.85 M USD
Jan 1, 2008
810,000 USD
-7.1 M USD
-9 M USD
Jan 1, 2009
650,000 USD
-6.93 M USD
-9.03 M USD
Jan 1, 2010
660,000 USD
-9.14 M USD
-13.01 M USD
Jan 1, 2011
18.99 M USD
-7.79 M USD
89.36 M USD
Jan 1, 2012
39.34 M USD
-50.24 M USD
-73.36 M USD
Jan 1, 2013
29.52 M USD
-61.6 M USD
-63.23 M USD
Jan 1, 2014
23.84 M USD
-67.85 M USD
-74.28 M USD
Jan 1, 2015
19.76 M USD
-91.79 M USD
-96.24 M USD
Jan 1, 2016
42.55 M USD
-18.47 M USD
-4.13 M USD
Jan 1, 2017
2.41 M USD
-90.17 M USD
-76.82 M USD
Jan 1, 2018
17.34 M USD
-64.31 M USD
-35.29 M USD
Jan 1, 2019
16.72 M USD
-86.47 M USD
-89.8 M USD
Jan 1, 2020
32.16 M USD
-73.49 M USD
-77.94 M USD
Access this data via the Eulerpool API
Get Free API Key

Mesoblast Income Statement, Balance Sheet, Cash Flow Statement

Last updated Mar 31, 2026, 3:28 AM
 
REVENUE (B USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M USD)
NET INCOME (M USD)
NET INCOME GROWTH (%)
SHARES (B)
DOCUMENTS
202420252026e2027e2028e2029e2030e2031e
0.010.020.130.180.350.970.941.37
-28.57240652.9438.2899.44174.22-2.6945.86
-18070.599.386.783.41.241.270.87
-912121212121212
-87-102-17158442730--
7.4117.2467.65-133.92662.0765.16––
0.991.211.211.211.211.211.211.21
––––––––
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Mesoblast generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Mesoblast retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Mesoblast's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Mesoblast has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Mesoblast's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Access this data via the Eulerpool API
Get Free API Key

Mesoblast stock margins

The Mesoblast margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mesoblast. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mesoblast.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
70.17 %
-222.75 %
-293.84 %
Jan 1, 2007
70.17 %
-416.67 %
-518.94 %
Jan 1, 2008
70.17 %
-876.54 %
-1,111.11 %
Jan 1, 2009
70.17 %
-1,066.15 %
-1,389.23 %
Jan 1, 2010
70.17 %
-1,384.85 %
-1,971.21 %
Jan 1, 2011
70.17 %
-41.02 %
470.56 %
Jan 1, 2012
42.3 %
-127.71 %
-186.48 %
Jan 1, 2013
27.24 %
-208.67 %
-214.19 %
Jan 1, 2014
-6.25 %
-284.61 %
-311.58 %
Jan 1, 2015
-20.35 %
-464.52 %
-487.04 %
Jan 1, 2016
30.05 %
-43.4 %
-9.7 %
Jan 1, 2017
-400.21 %
-3,738.47 %
-3,184.7 %
Jan 1, 2018
68.24 %
-370.85 %
-203.51 %
Jan 1, 2019
8.16 %
-517.08 %
-537.01 %
Jan 1, 2020
21.29 %
-228.55 %
-242.38 %
Access this data via the Eulerpool API
Get Free API Key

Mesoblast Stock Revenue, EBIT, Earnings per Share

The Mesoblast earnings per share therefore indicates how much revenue Mesoblast has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
0.02 USD
-0.05 USD
-0.07 USD
Jan 1, 2007
0.01 USD
-0.05 USD
-0.06 USD
Jan 1, 2008
0.01 USD
-0.06 USD
-0.08 USD
Jan 1, 2009
0.01 USD
-0.06 USD
-0.07 USD
Jan 1, 2010
0 USD
-0.06 USD
-0.09 USD
Jan 1, 2011
0.08 USD
-0.03 USD
0.39 USD
Jan 1, 2012
0.14 USD
-0.18 USD
-0.26 USD
Jan 1, 2013
0.1 USD
-0.21 USD
-0.21 USD
Jan 1, 2014
0.07 USD
-0.21 USD
-0.23 USD
Jan 1, 2015
0.06 USD
-0.28 USD
-0.3 USD
Jan 1, 2016
0.12 USD
-0.05 USD
-0.01 USD
Jan 1, 2017
0.01 USD
-0.23 USD
-0.19 USD
Jan 1, 2018
0.04 USD
-0.14 USD
-0.08 USD
Jan 1, 2019
0.03 USD
-0.17 USD
-0.18 USD
Jan 1, 2020
0.06 USD
-0.14 USD
-0.15 USD
Access this data via the Eulerpool API
Get Free API Key

Mesoblast business model & stock analysis

Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future.

Mesoblast SWOT Analysis

Strengths

Mesoblast Ltd has a diverse portfolio of cell therapy products in various stages of development.

The company has a strong intellectual property portfolio, providing a competitive advantage.

Mesoblast has established partnerships and collaborations with reputable pharmaceutical companies.

Weaknesses

Mesoblast faces challenges in successfully commercializing its cell therapy products.

The company relies heavily on the success of its clinical trials, which pose inherent risks.

There is a dependence on external funding sources to support ongoing research and development.

Opportunities

The growing demand for innovative cell-based therapies presents significant market opportunities for Mesoblast.

Expansion into new geographic regions can help Mesoblast tap into underserved markets.

The increasing prevalence of chronic diseases provides a target patient population for Mesoblast's products.

Threats

Competition from other companies in the cell therapy space poses a threat to Mesoblast's market share.

Regulatory constraints and evolving regulations may impact the company's ability to gain necessary approvals for its products.

Changes in reimbursement policies and healthcare systems could affect the affordability and accessibility of Mesoblast's therapies.

Access this data via the Eulerpool API
Get Free API Key

Mesoblast Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Access this data via the Eulerpool API
Get Free API Key

Mesoblast historical P/E ratio, EBIT multiple, and P/S ratio

Access this data via the Eulerpool API
Get Free API Key
Access this data via the Eulerpool API
Get Free API Key

Mesoblast shares outstanding

The number of shares was Mesoblast in 2025 — This indicates how many shares 1.208 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
94.45 M base_Shares
Jan 1, 2007
107.52 M base_Shares
Jan 1, 2008
115.36 M base_Shares
Jan 1, 2009
125.47 M base_Shares
Jan 1, 2010
141.99 M base_Shares
Jan 1, 2011
230.06 M base_Shares
Jan 1, 2012
285.72 M base_Shares
Jan 1, 2013
295.73 M base_Shares
Jan 1, 2014
322.68 M base_Shares
Jan 1, 2015
324.11 M base_Shares
Jan 1, 2016
364.44 M base_Shares
Jan 1, 2017
399.3 M base_Shares
Jan 1, 2018
465.69 M base_Shares
Jan 1, 2019
494.38 M base_Shares
Jan 1, 2020
528.82 M base_Shares
Access this data via the Eulerpool API
Get Free API Key
Price targets and forecasts for Mesoblast are not yet available.
Access this data via the Eulerpool API
Get Free API Key

Mesoblast Earnings Estimates

Mesoblast Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
2/21/2024-0.11USD2.02 MUSD2024 Q2
8/29/2023-0.06USD12.18 MUSD2023 Q4
2/23/2023-0.07USD11.16 MUSD2023 Q2
8/31/2022-0.04USD15.73 MUSD2022 Q4
2/25/2022-0.06USD-USD2022 Q2
8/31/2021-0.03USD-USD2021 Q4
2/17/2016-0.22USD-USD2016 Q2
8/17/2015-0.08USD49.4 MUSD2015 Q4
8/29/2013-0.13USD-USD2013 Q4
2/11/2013-0.12USD17.07 MUSD2013 Q2

EESG©

Eulerpool ESG Scorecard© for the Mesoblast stock

55/100
55
Environment
99
Social
11
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees52
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Access this data via the Eulerpool API
Get Free API Key

Mesoblast shareholder structure

% Name
10.62212%
George (Gregory)
George (Gregory)
10.49251%
G to the Fourth Investments LLC
G to the Fourth Investments LLC
6.53745%
Itescu (Silviu)
Itescu (Silviu)
5.31315%
Gueck (William)
Gueck (William)
3.72323%
State Street Investment Management Australia Ltd.
State Street Investment Management Australia Ltd.
3.38306%
M&G Investment Management Ltd.
M&G Investment Management Ltd.
2.3672%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.55183%
Vanguard Investments Australia Ltd.
Vanguard Investments Australia Ltd.
1.16878%
Thorney International Pty. Ltd.
Thorney International Pty. Ltd.
0.99528%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
...
Access this data via the Eulerpool API
Get Free API Key

Mesoblast Executives and Management Board

SI

Dr. Silviu Itescu

Chief Executive Officer, Executive Director · since 2004

Compensation3.02 M USD
ER

Dr. Eric Rose

(73)

Executive Director, Chief Medical Officer · since 2013

Compensation2.29 M USD
PK

Mr. Philip Krause

Non-Executive Independent Director

Compensation515,271 USD
JB

Mrs. Jane Bell

Non-Executive Independent Chairman of the Board

Compensation230,424 USD
WB

Mr. William Burns

(77)

Non-Executive Independent Vice Chairman of the Board · since 2014

Compensation200,974 USD
Access this data via the Eulerpool API
Get Free API Key

Frequently asked questions about Mesoblast

The business model of Mesoblast Ltd revolves around developing and commercializing innovative cellular medicines. As a leading global biopharmaceutical company, Mesoblast focuses on leveraging its proprietary allogeneic cell therapy platform to address significant unmet medical needs. By harnessing the power of mesenchymal lineage adult stem cells, Mesoblast aims to deliver effective treatments across a broad range of inflammatory and immune-mediated diseases, cardiovascular conditions, and orthopedic disorders. This commitment to pioneering research and development, coupled with strategic collaborations and a strong intellectual property portfolio, enables Mesoblast to transform the lives of patients worldwide through the potential of regenerative medicine.

Access this data via the Eulerpool API
Get Free API Key

All fundamentals and in-depth analysis of Mesoblast

Our stock analysis for Mesoblast Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mesoblast Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Mesoblast Stock
Mesoblast Revenue→
Mesoblast Stock
Mesoblast Net Income→
Mesoblast Stock
Mesoblast P/E→
Mesoblast Stock
Mesoblast P/S→
Mesoblast Stock
Mesoblast EBIT→
Mesoblast Stock
Mesoblast Dividend→
Mesoblast Stock
Mesoblast Directors Dealings→
Mesoblast Stock
Mesoblast Stocks→
Mesoblast Stock
Mesoblast Market capitalization→
Mesoblast Stock
Mesoblast Debt→
Mesoblast Stock
Mesoblast Liabilities→
Mesoblast Stock
Mesoblast Equity→
Mesoblast Stock
Mesoblast AAQS→
Mesoblast Stock
Mesoblast Employees→
Mesoblast Stock
Mesoblast ROE→
Mesoblast Stock
Mesoblast ROA→
Mesoblast Stock
Mesoblast ROCE→